{
  "id": "clinical#screening_cues_9e99efbb",
  "content": "Other Specified Insomnia Disorder 197\nthat is presumed to be causing the sleep disturbance. The diagnostic\ncode is selected from the table included in the criteria set, which is\nbased on the drug class and presence or absence of a comorbid sub-\nstance use disorder. For substances that do not fit into any of the\nclasses (e.g., bupropion), the code for “other substance” should be\nused; and in cases in which a substance is judged to be an etiological\nfactor but the specific class of substance is unknown, the category “un-\nknown substance” should be used.\nWhen recording the name of the disorder, the comorbid sub-\nstance use disorder (if any) is listed first, followed by the word\n“with,” followed by the name of the substance-induced sleep disor-\nder, followed by the specification of onset (i.e., onset during intoxi-\ncation, onset during discontinuation/withdrawal), followed by the\nsubtype designation (i.e., insomnia type, daytime sleepiness type,\nparasomnia type, mixed type). For example, in the case of insomnia\noccurring during withdrawal in a man with a severe lorazepam use\ndisorder, the diagnosis is F13.282 severe lorazepam use disorder with\nlorazepam-induced sleep disorder, with onset during withdrawal,",
  "metadata": {
    "source": "DSM-5",
    "url": "https://psychiatry.org/",
    "condition": "General",
    "risk_band": "low",
    "topics": [
      "sleep",
      "study",
      "screening_cues"
    ],
    "is_clinical": true,
    "is_advice": false
  },
  "index_text": "General — Screening Cues Other Specified Insomnia Disorder 197\nthat is presumed to be causing the sleep disturbance. The diagnostic\ncode is selected from the table included in the criteria set, which is\nbased on the drug class and presence or absence of a comorbid sub-\nstance use disorder. For substances that do not fit into any of the\nclasses (e.g., bupropion), the code for “other substance” should be\nused; and in cases in which a substance is judged to be an etiological\nfactor but the specific class of substance is unknown, the category “un-\nknown substance” should be used.\nWhen recording the name of the disorder, the comorbid sub-\nstance use disorder (if any) is listed first, followed by the word\n“with,” followed by the name of the substance-induced sleep disor-\nder, followed by the specification of onset (i.e., onset during intoxi-\ncation, onset during discontinuation/withdrawal), followed by the\nsubtype designation (i.e., insomnia type, daytime sleepiness type,\nparasomnia type, mixed type). For example, in the case of insomnia\noccurring during withdrawal in a man with a severe lorazepam use\ndisorder, the diagnosis is F13.282 severe lorazepam use disorder with\nlorazepam-induced sleep disorder, with onset during withdrawal, Other specified insomnia disorder 197\nthat is presumed to be causing the giấc ngủ disturbance. the diagnostic\ncode is selected from the table included in the criteria set, which is\nbased on the drug class and presence or..."
}